HilleVax, Inc.

NasdaqGS HLVX

HilleVax, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 638.00 K

HilleVax, Inc. Gross Profit is USD 638.00 K for the Trailing 12 Months (TTM) ending September 30, 2024, a 117.32% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

HilleVax, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -3.68 M, a -184,100.00% change year over year.
HilleVax, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.00 K, a -100.00% change year over year.
HilleVax, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -1.00 K.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqGS: HLVX

HilleVax, Inc.

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date	April 29, 2022
Location	United States
Headquarters	75 State Street
Employees	90
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Key trends

Past 5 years